ClinicalTrials.gg

Program

TQB3702 tablets+Chemotherapy regimen

A development code.

In Sino Biopharmaceutical’s pipeline, BTK抑制剂. Its studies are mostly in Lymphoma, B-Cell, led by Sino Biopharmaceutical.

Furthest: phase 2, since Aug 21, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 2since Aug 21, 2024Aug 21, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3702, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2024First study: phase 2 study in Lymphoma, B-CellFirst studyNCT06566586 · 80 planned · China

TargetBeta

“BTK抑制剂”the company's pipeline, read by Claude · source

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06566586Lymphoma, B-Cell · China2RecruitingMar 202680

How it is read

Names in the registry

  • “TQB3702 tablets+Chemotherapy regimen”, 1 entry

Codes read as this program: TQB3702.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.